Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
Observational Cohort Study to Evaluate the Safety and Efficacy of Pradaxa (Dabigatran Etexilate) for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery in a Routine Clinical Setting.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Croom、アイルランド
- 1160.85.35301 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Basildon、イギリス
- 1160.85.04405 Boehringer Ingelheim Investigational Site
-
Gateshead、イギリス
- 1160.85.04406 Boehringer Ingelheim Investigational Site
-
Halifax、イギリス
- 1160.85.04402 Boehringer Ingelheim Investigational Site
-
London、イギリス
- 1160.85.04404 Boehringer Ingelheim Investigational Site
-
Luton、イギリス
- 1160.85.04403 Boehringer Ingelheim Investigational Site
-
Wigan、イギリス
- 1160.85.04401 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bari、イタリア
- 1160.85.03911 Boehringer Ingelheim Investigational Site
-
Firenze、イタリア
- 1160.85.03905 Boehringer Ingelheim Investigational Site
-
Genova、イタリア
- 1160.85.03904 Boehringer Ingelheim Investigational Site
-
Jesi (an)、イタリア
- 1160.85.03906 Boehringer Ingelheim Investigational Site
-
Latina、イタリア
- 1160.85.03914 Boehringer Ingelheim Investigational Site
-
Mantova、イタリア
- 1160.85.03901 Boehringer Ingelheim Investigational Site
-
Ome (bs)、イタリア
- 1160.85.03913 Boehringer Ingelheim Investigational Site
-
Roma、イタリア
- 1160.85.03907 Boehringer Ingelheim Investigational Site
-
Torino、イタリア
- 1160.85.03909 Boehringer Ingelheim Investigational Site
-
Vimercate (mi)、イタリア
- 1160.85.03910 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Graz、オーストリア
- 1160.85.4308 Boehringer Ingelheim Investigational Site
-
Klagenfurt、オーストリア
- 1160.85.4309 Boehringer Ingelheim Investigational Site
-
Linz、オーストリア
- 1160.85.4303 Boehringer Ingelheim Investigational Site
-
Linz、オーストリア
- 1160.85.4304 Boehringer Ingelheim Investigational Site
-
St. Johann/Tirol、オーストリア
- 1160.85.4305 Boehringer Ingelheim Investigational Site
-
Stolzalpe、オーストリア
- 1160.85.4312 Boehringer Ingelheim Investigational Site
-
Wels、オーストリア
- 1160.85.4307 Boehringer Ingelheim Investigational Site
-
Wien、オーストリア
- 1160.85.4301 Boehringer Ingelheim Investigational Site
-
Wien、オーストリア
- 1160.85.4302 Boehringer Ingelheim Investigational Site
-
Wien、オーストリア
- 1160.85.4310 Boehringer Ingelheim Investigational Site
-
Wien、オーストリア
- 1160.85.4311 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kungälv、スウェーデン
- 1160.85.4603 Boehringer Ingelheim Investigational Site
-
Motala、スウェーデン
- 1160.85.4601 Boehringer Ingelheim Investigational Site
-
Solleftea、スウェーデン
- 1160.85.4604 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Madrid、スペイン
- 1160.85.3404 Boehringer Ingelheim Investigational Site
-
Madrid、スペイン
- 1160.85.3406 Boehringer Ingelheim Investigational Site
-
Malaga、スペイン
- 1160.85.3405 Boehringer Ingelheim Investigational Site
-
Pamplona、スペイン
- 1160.85.3407 Boehringer Ingelheim Investigational Site
-
Valencia、スペイン
- 1160.85.3401 Boehringer Ingelheim Investigational Site
-
Zaragoza、スペイン
- 1160.85.3402 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bad Homburg、ドイツ
- 1160.85.04924 Boehringer Ingelheim Investigational Site
-
Bayreuth、ドイツ
- 1160.85.04926 Boehringer Ingelheim Investigational Site
-
Berlin、ドイツ
- 1160.85.04903 Boehringer Ingelheim Investigational Site
-
Bochum、ドイツ
- 1160.85.04931 Boehringer Ingelheim Investigational Site
-
Breitenbrunn、ドイツ
- 1160.85.04930 Boehringer Ingelheim Investigational Site
-
Chemnitz、ドイツ
- 1160.85.04923 Boehringer Ingelheim Investigational Site
-
Erlangen、ドイツ
- 1160.85.04947 Boehringer Ingelheim Investigational Site
-
Fürth、ドイツ
- 1160.85.04945 Boehringer Ingelheim Investigational Site
-
Garmische-Partenkirchen、ドイツ
- 1160.85.04912 Boehringer Ingelheim Investigational Site
-
Gelnhausen、ドイツ
- 1160.85.04922 Boehringer Ingelheim Investigational Site
-
Gelsenkirchen、ドイツ
- 1160.85.04917 Boehringer Ingelheim Investigational Site
-
Günzburg、ドイツ
- 1160.85.04949 Boehringer Ingelheim Investigational Site
-
Hachenburg、ドイツ
- 1160.85.04927 Boehringer Ingelheim Investigational Site
-
Hamburg、ドイツ
- 1160.85.04910 Boehringer Ingelheim Investigational Site
-
Hannover、ドイツ
- 1160.85.04906 Boehringer Ingelheim Investigational Site
-
Hof、ドイツ
- 1160.85.04920 Boehringer Ingelheim Investigational Site
-
Kamp-Linfort、ドイツ
- 1160.85.04916 Boehringer Ingelheim Investigational Site
-
Kassel、ドイツ
- 1160.85.04939 Boehringer Ingelheim Investigational Site
-
Koblenz、ドイツ
- 1160.85.04929 Boehringer Ingelheim Investigational Site
-
Landstuhl、ドイツ
- 1160.85.04909 Boehringer Ingelheim Investigational Site
-
Lübben、ドイツ
- 1160.85.04944 Boehringer Ingelheim Investigational Site
-
Mainz、ドイツ
- 1160.85.04935 Boehringer Ingelheim Investigational Site
-
Marburg、ドイツ
- 1160.85.04902 Boehringer Ingelheim Investigational Site
-
Markgröningen、ドイツ
- 1160.85.04934 Boehringer Ingelheim Investigational Site
-
Marktheidenfeld、ドイツ
- 1160.85.04918 Boehringer Ingelheim Investigational Site
-
Merseburg、ドイツ
- 1160.85.04941 Boehringer Ingelheim Investigational Site
-
Minden、ドイツ
- 1160.85.04952 Boehringer Ingelheim Investigational Site
-
München、ドイツ
- 1160.85.04943 Boehringer Ingelheim Investigational Site
-
München、ドイツ
- 1160.85.04946 Boehringer Ingelheim Investigational Site
-
Nürnberg、ドイツ
- 1160.85.04904 Boehringer Ingelheim Investigational Site
-
Olsberg、ドイツ
- 1160.85.04913 Boehringer Ingelheim Investigational Site
-
Pfortzheim、ドイツ
- 1160.85.04932 Boehringer Ingelheim Investigational Site
-
Rosenheim、ドイツ
- 1160.85.04901 Boehringer Ingelheim Investigational Site
-
Rostock、ドイツ
- 1160.85.04915 Boehringer Ingelheim Investigational Site
-
Rostock、ドイツ
- 1160.85.04928 Boehringer Ingelheim Investigational Site
-
Rotenburg/Fulda、ドイツ
- 1160.85.04936 Boehringer Ingelheim Investigational Site
-
Schwarzenbruck、ドイツ
- 1160.85.04905 Boehringer Ingelheim Investigational Site
-
Sylt、ドイツ
- 1160.85.04914 Boehringer Ingelheim Investigational Site
-
Wertheim、ドイツ
- 1160.85.04933 Boehringer Ingelheim Investigational Site
-
Wiesbaden、ドイツ
- 1160.85.04921 Boehringer Ingelheim Investigational Site
-
Wismar、ドイツ
- 1160.85.04938 Boehringer Ingelheim Investigational Site
-
Worms、ドイツ
- 1160.85.04907 Boehringer Ingelheim Investigational Site
-
Würzburg、ドイツ
- 1160.85.04940 Boehringer Ingelheim Investigational Site
-
Würzburg、ドイツ
- 1160.85.04948 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Angers、フランス
- 1160.85.3306A Boehringer Ingelheim Investigational Site
-
Bois Guillaume Cédex、フランス
- 1160.85.3318A Boehringer Ingelheim Investigational Site
-
Bordeaux、フランス
- 1160.85.3333A Boehringer Ingelheim Investigational Site
-
Caen Cedex 9、フランス
- 1160.85.3310A Boehringer Ingelheim Investigational Site
-
Clermont-Ferrand cedex 1、フランス
- 1160.85.3311A Boehringer Ingelheim Investigational Site
-
Creteil、フランス
- 1160.85.3315A Boehringer Ingelheim Investigational Site
-
DIJON Cédex、フランス
- 1160.85.3305A Boehringer Ingelheim Investigational Site
-
Illkirch、フランス
- 1160.85.3304A Boehringer Ingelheim Investigational Site
-
Le Havre、フランス
- 1160.85.3334A Boehringer Ingelheim Investigational Site
-
Les Lilas、フランス
- 1160.85.3324A Boehringer Ingelheim Investigational Site
-
Lille cedex、フランス
- 1160.85.3309A Boehringer Ingelheim Investigational Site
-
Lyon、フランス
- 1160.85.3307A Boehringer Ingelheim Investigational Site
-
Marseille、フランス
- 1160.85.3325A Boehringer Ingelheim Investigational Site
-
Metz、フランス
- 1160.85.3323A Boehringer Ingelheim Investigational Site
-
Nantes Cédex 2、フランス
- 1160.85.3321A Boehringer Ingelheim Investigational Site
-
Paris、フランス
- 1160.85.3303A Boehringer Ingelheim Investigational Site
-
Paris、フランス
- 1160.85.3320A Boehringer Ingelheim Investigational Site
-
Paris cedex 10、フランス
- 1160.85.3301A Boehringer Ingelheim Investigational Site
-
Paris cedex 14、フランス
- 1160.85.3302A Boehringer Ingelheim Investigational Site
-
Pierre Bénite cedex、フランス
- 1160.85.3308A Boehringer Ingelheim Investigational Site
-
Poitiers Cédex、フランス
- 1160.85.3322A Boehringer Ingelheim Investigational Site
-
Saint Etienne Cédex 2、フランス
- 1160.85.3319A Boehringer Ingelheim Investigational Site
-
Saint Saulve、フランス
- 1160.85.3317A Boehringer Ingelheim Investigational Site
-
Toulouse Cedex 9、フランス
- 1160.85.3314A Boehringer Ingelheim Investigational Site
-
Toulouse Cédex 9、フランス
- 1160.85.3313A Boehringer Ingelheim Investigational Site
-
Vannes Cédex、フランス
- 1160.85.3331A Boehringer Ingelheim Investigational Site
-
-
-
-
-
Koscierzyna、ポーランド
- 1160.85.4805 Boehringer Ingelheim Investigational Site
-
Lodz、ポーランド
- 1160.85.4804 Boehringer Ingelheim Investigational Site
-
Otwock、ポーランド
- 1160.85.4803 Boehringer Ingelheim Investigational Site
-
Piekary Slaskie、ポーランド
- 1160.85.4802 Boehringer Ingelheim Investigational Site
-
Swiebodzin、ポーランド
- 1160.85.4806 Boehringer Ingelheim Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion criteria:
Patients of 18 years of age or above undergoing elective total hip or knee replacement surgery who consent in writing to their participation in this observational study
Exclusion criteria:
All patients who should not be treated with Pradaxa 220 mg according to the European Summary of Product Characteristics (SPC): age of > 75 years, renal impairment (creatinine clearance <50 ml/min), patients with concomitant therapy of amiodarone, elevated liver enzymes > 2 upper limit of normal (ULN) and/or hepatic impairment or liver disease expected to have any impact on survival, anaesthesia with post operative indwelling epidural catheters, hypersensitivity to dabigatran etexilate or to any of the excipients, active clinically significant bleeding, organic lesion at risk of bleeding, spontaneous or pharmacological impairment of haemostasis except for the above included patients groups, concomitant treatment with quinidine
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Patients 75 years or younger
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percentage of Patients With Major Bleeding Events (MBE) During Treatment Period
時間枠:From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Major bleeding events were defined according to the modified McMaster criteria, and were classified by the investigator as Major bleeding event or Any bleeding event.
The criteria for MBE's were: fatal; clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected; clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected; symptomatic retroperitoneal, intracranial, intraocular or intraspinal; requiring treatment cessation; leading to re-operation
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Percentage of Patients With Symptomatic Venous Thromboembolic Events (sVTE) and All Cause Mortality
時間枠:From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
The co-primary efficacy variable sVTE was defined as the composite of documented symptomatic proximal and distal deep vein thrombosis (DVT) and documented symptomatic non-fatal pulmonary embolism (PE).
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percentage of Patients With Major Extra-surgical Site Bleedings
時間枠:From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
|
Volume of Wound Drainage (Post-operative)
時間枠:From end of surgery (before first dosing) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Total volume of wound drainage is calculated as sum of volume drainage from end of surgery until first dose of Pradaxa plus volume drainage from first dose of Pradaxa and onwards.
|
From end of surgery (before first dosing) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
Percentage of Patients With Single Components of Composite of sVTE and All-cause Mortality
時間枠:From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
From first intake (day of surgery) until 24 hours after last intake (planned: knee replacement: Day 10 after surgery, hip replacement: Day 28-35 after surgery) of Pradaxa
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。